CLINICAL_TRIALS
trial_result
· 2016-11-11
Clinical Trial Update: Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation [Phase 2]
Summary
This document provides an update on a Phase 2 clinical trial evaluating icotinib in non-small cell lung cancer patients with uncommon EGFR mutations.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chinese Academy of Medical Sciences | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN